Revenue ($USD): $2,791,041,000
R&D spend: $153,819,000.00
Employees: 15,500
Fiscal year end: 12/31/22
CEO: Liam Kelly
It picked up where it left off last year in terms of M&A with a urology play in the form of its$650 million deal to acquire Palette Life Sciencesin July.–SW